



Evolution of technology diffusion within Brazilian Universal healthcare system (*Sistema Único de Saúde - SUS*) 2+ years after listing of antiangiogenics treatment for age-related macular edema (AMD)

Authors: Rodolfo Mattar; Pedro Nogueira; Daniela Foli; Glauco Britto; Ricardo Saad

Background & Rationale

The risk of developing age-related macular edema (AMD) increases along life and reaches 15% of people >60 years old. Considering that neovascular type of AMD is among the leading causes of vision impairment and blindness, providing treatment for this condition becomes a matter of public health.

Antiangiogenic drugs are available for AMD treatment in many countries worldwide, since they are the gold-standard choice for these patients. Since April/2022, antiangiogenics have been listed by the Brazilian Universal Healthcare System (*Sistema Único de Saúde - SUS*).

Technology diffusion management after listing by healthcare systems is challenging, considering it relies on multiple factors that are context and/or technology-specific. For example, in terms of context, Brazil has continental dimensions and distinct characteristics throughout the territory, what makes more difficult to reach all the corners of the country equally. Besides, antiangiogenics technologies require cold chain logistics and intravitreal administration must be performed in referenced institutions by qualified ophthalmologists (retina specialists), increasing their complexity of usage.


Objectives

This study focused on describing the current picture of antiangiogenics usage within SUS after listing. Analysis were based on the influence of infrastructure of the healthcare system over technology diffusion.

To assess the effectiveness of antiangiogenics diffusion, real-world data was gathered along 29 months post-listing (from April/2022 to August/2024).

Methods

Data Mining of the SUS database (DataSUS)




Projections & Statistics

- Populational coverage of AMD treatment:** percentage was calculated based on epidemiology of AMD in Brazil and total number of treated patients under SUS.
- Influence of infrastructure for technology diffusion:** Pearson Correlation (PC) and R-squared (R^2) were calculated to estimate the influence of referenced institutions over populational coverage, naïve patients starting treatment and number of antiangiogenics injection administered.
- Antiangiogenics posology:** assessed by calculating the average number of injections administered per patient during the timeframe analyzed.

Results

Along the months studied, the number of referenced institutions increased 69% (83 to 140 institutions), demonstrating the growth of system's infrastructure. This increment is positively correlated with augmentation of populational coverage, number of naïve patients starting treatment and total antiangiogenics injections administered. During the 29-months period, the average number of antiangiogenics injections per AMD-patient was 3.91.



Conclusions

Implementing public policies for healthcare in Brazil is a complex endeavor, particularly because of the territory extension and size of the population. Besides, antiangiogenics usage requires specific infrastructure that increases barriers for technology diffusion throughout the healthcare system. Therefore, we hypothesized that referenced institutions are the main bottleneck in this scenario, since they can store antiangiogenics molecules and provide qualified medical services at the same time.

This hypothesis is reinforced by the positive correlation we found between increased number of centers and growth of populational coverage, treatment of more naïve patients and augmented number of intravitreal injections administration. **That data corroborates with the need of implementing more referenced institution for expanding antiangiogenics usage and enlarging number of patients treated**, in this context, percentage of populational coverage might increase.

Although the constant increase of antiangiogenics diffusion along time, **the mean number of intravitreal injections per patient (3.91 injections/patient) indicates undertreatment**, since all the molecules listed for AMD require more injections than what has been performed. Despite we do not have information about market share of antiangiogenics in SUS, the mean number of injections used for each antiangiogenic is higher than the current practice (bevacizumab: 8.9; ranibizumab: 8.0; aflibercept: 7.1 injections/patient in the first year of treatment).

In summary, although investing on infrastructure might expand antiangiogenics diffusion and populational coverage, it is also important to find ways of increasing average number of injections per patient to assure proper treatment effectiveness.

Bibliography

- Canadian Agency for Drugs and Technologies in Health (CADTH) for the Health Technology Strategy Policy Forum. Discussion Paper: Managing Technology Diffusion. James Murtagh and Vicki Foerster. October 2009.
- MacCumber MW, Yu JS, Sakiotis A, B G, Burugapalli B, Bi X, Agashivala N, Wykoff CC. Anti-vascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis. *Can J Ophthalmol*. 2023 Jun;58(3):252-261.
- Lee A, Garg PG, Lyon AT, Mirza R, Gill MK. Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration. *J Ophthalmic Vis Res*. 2020 Aug 6;15(3):331-340.
- Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes. *Ophthalmol Retina*. 2020 Jan;4(1):19-30.
- Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAR Investigators. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAR - A Randomized Controlled Trial. *Adv Ther*. 2020 Mar;37(3):1173-1187.
- Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge S, Herschsen H, Fossen K, Markovic S, Pedersen TR, Sandvik L, Bragadottir R. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results. *Ophthalmology*. 2016 Jan;123(1):51-9.

